The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Cold Chain Logistics Market for Vaccines (including Coronavirus (COVID-19 Vaccine)) by Type of Services (Storage, Packaging, and Transportation), Mode of Transportation (Ground, Air, and Ocean), Holding Temperature (Ambient, Refrigerated, Frozen, and Deep Frozen / Cryogenic), Type of Packaging Methods (Dry Ice, Liquid Nitrogen, and Gel Packs), Regions (North America, Europe, Asia-Pacific, Latin America, MENA and RoW): Industry Trends and Global Forecasts, 2021-2030 [Upcoming Report]

  • Lowest Price Guaranteed From USD 5,499

  • Published
    January 2021

  • Pages
    296

  • View Count
    394

Example Insights

[Available on Request]

Overview

Over 95% of all approved biologics and 90% of all vaccines are cold chain dependent.  According to the data presented by the WHO, the current global vaccination coverage is nearly 85%; however, it has been reported that 25% of vaccines are damaged due to cold chain malfunction (improper distribution and shipping). In some countries, about 80% of the drugs are estimated to lose their potency due to inadequate temperature control during their cold chain transportation. For some vaccines, even the slightest variations in temperature / storage conditions can adversely alter product integrity and / or viability. In this context, it is worth mentioning that there are several vaccines being developed against COVID-19; given the nature of the pathogen, these aforementioned product candidates are likely to be cold chain dependent. For example, the synthetic mRNA-based COVID vaccine being developed by Pfizer (which is, so far, the most promising candidate) is required to be stored at -70°C (-94°F) or lower. This fundamentally complicates the use and cold chain distribution for vaccines in temperate / equatorial regions, where distances between populated regions are vast and a proper cold chain infrastructure is lacking. Other healthcare products that need to be shipped / stored under low temperatures include aerosols, blood plasma, and certain diagnostics kits.

Considering the projected growth of the global population, it is likely that the demand for vaccines will indubitably increase. Consequently, well-defined cold chain infrastructure and established vaccine supply networks are crucial to the success of global level immunization initiatives. This is also true for all vaccination programs for COVID-19, which is an immediate and exigent concern. In other words, the biggest challenge in cold chain logistics is lack of / inadequate infrastructure to support the cold chain storage and / or transportation of vaccines.  Moreover, connected cold chain solutions have been observed to offer a variety of advantages over conventional methodologies, such as automation of most of the steps and elimination of human handling errors that are associated with human intervention.  

Over time, there has been significant consolidation in this industry, with stakeholders expanding their respective facilities / capabilities, and also making strategic acquisitions to better serve their growing clientele. Further, the logistics service providers are focused on devising and implementing flexible business strategies and technical advancements in order to cope with increased inflow of patients. The countries are also preparing for sustainable cold chain storage and distribution / supply of COVID-19 vaccine to different parts of globe, as the reliance on cold chain facilities for coronavirus vaccine is expected to increase substantially.

Scope of the Report

The ‘Cold Chain Logistics Market for Vaccines (including Coronavirus (COVID-19 Vaccine)) by Type of Services (Storage, Packaging, and Transportation), Mode of Transportation (Ground, Air, and Ocean), Holding Temperature (Ambient, Refrigerated, Frozen, and Deep Frozen / Cryogenic), Type of Packaging Methods (Dry Ice, Liquid Nitrogen, and Gel Packs), Type of Container (Active and Passive Containers), End-Users (Industry Players and Non-Industry Players), Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts, 2021-2030, report features an extensive study of the current landscape, offering an informed opinion on the likely evolution of this industry, over the next ten years. Further, the study underlines an in-depth analysis of players engaged in offering cold chain logistics services for vaccines. Amongst other elements, the report features:

  • A detailed assessment of the current market landscape of companies that claim to offer cold chain logistics services for vaccines based on a number of relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, type of service(s) offered (storage, packaging, and transportation), mode of transportation used (ground, air, and ocean), holding temperature range (ambient, refrigerated, frozen, and deep frozen / cryogenic), type of packaging method adopted (dry ice, liquid nitrogen, and gel packs), type of container used (active and passive containers), end-user (industry players and non-industry players), availability of capabilities for transport of COVID-19 vaccine, location of cold chain facilities. In addition, the chapter includes a list of cold chain equipment / technologies and monitoring systems, along with the information on their developers.
  • A contemporary market trend analysis, which includes [A] a tree map representation, comparing industry players on the basis of holding temperature range and company size, [B] a heat map representation comparing players on the basis of holding temperature range and type of packaging method, [C] a grid representation which highlights the distribution of players based on mode of transportation, type of container and region, and [D] a world map representation presenting the regional distribution of players engaged in this domain based on the location of their respective headquarters.
  • An insightful company competitiveness analysis, highlighting prominent logistics service providers based in different regions, taking into consideration their supplier strength (in terms of experience of the service provider), and capabilities related to cold chain logistics (such as type of container, type of service(s) offered, holding temperature range, mode of transportation and location of cold chain facility). 
  • Elaborate profiles of prominent service providers (shortlisted on the basis of the company competitiveness analysis) engaged in this domain. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key members of the executive team), details related to their respective portfolios for cold chain services, recent developments, and an informed future outlook. 
  • An elaborate discussion on the various regulatory guidelines that have been laid down by major regulatory bodies (such as European Medicines Agency (EMA), United States Food and Drug Administration (USFDA), Health Canada (HC), International Air Transport Association (IATA), International Safe Transit Association (ISTA), United States Pharmacopeia (USP), and World Health Organization (WHO)), specific to cold chain management. In addition, it features an insightful analysis, comparing these regulatory authorities based on the guidelines issued by them for different stages of the cold chain.
  • A detailed analysis of the partnerships that have been established in the cold chain logistics market for vaccines, during the period between 2010 and 2020, covering service alliances, logistics services agreements, equipment development / manufacturing agreements, R&D agreements, joint ventures and other relevant deals.
  • An analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in terms of the number of companies acquired till 2020, along with the geographical distribution of this activity. 
  • A detailed estimation of the likely demand for logistics services for vaccines (including over 15 types of mandatory and optional vaccines), considering the contributions from both clinical and commercially available products for infants and adults, over the period 2020-2030.
  • A discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the cold chain logistics market for vaccines.
  • A detailed discussion on the upcoming tools / technologies (such as integration of automation and robotics, cloud computing, blockchain technology, artificial intelligence and other such advanced technical solutions) in the field of cold chain logistics and their likely impact on the future evolution of this market.
  • An insightful discussion on the impact of COVID-19 pandemic on the cold chain logistics market for vaccines.

One of the key objectives of the report was to estimate the existing market size and future growth potential within the cold chain logistics market for vaccines over the next decade. We have developed an informed estimate of the financial evolution of the market, over the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] holding temperature range (refrigerated, frozen, and cryogenic), [B] type of container (active and passive containers), [C] end-user (industry players and non-industry players), and [D] key geographical regions (North America, Europe, Asia-Pacific, Latin America (LATM), Middle East and North Africa (MENA) and Rest of the World). In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the industry’s evolution.

The opinions and insights presented in this study were also influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals (in alphabetical order): 

  • Elena Boykova (Marketing Communications Manager, AirBridgeCargo Airlines)
  • Jacqueline Barry (Chief Clinical Officer, Catapult Cell and Gene Therapy) 
  • Michelle Arnot-Kruger (Health Specialist, Cold Chain Logistics, UNICEF) 
  • Shehdeh Abusnineh (Supply Chain Manager, Tabuk Pharmaceuticals)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading players engaged in offering cold chain logistics services for vaccines, across the world?
  • Which regions are key hubs for cold chain related capabilities?
  • What are the key regulatory guidelines, related to cold chain storage / transportation of vaccines, that have been established across various geographies?
  • What are the most popular packaging methods used for cold chain logistics of vaccines?
  • What is the relative competitiveness of different cold chain logistics service providers engaged in this market? 
  • Which partnership models are most commonly adopted by stakeholders engaged in this industry?
  • How is the recent COVID-19 pandemic likely to impact the cold chain logistics market for vaccines?
  • What are the key challenges associated with storage and distribution of COVID-19 vaccines?
  • What is the current, global demand (clinical and commercial) for vaccines?
  • How is the current and future opportunity likely to be distributed across key market segments?
  • What are the anticipated future trends related to cold chain logistics market for vaccines?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of cold chain logistics market for vaccines in the short-mid term and long term.

Chapter 3 is an introductory chapter that provides a detailed comparison of the traditional supply chain and cold chain, along with information on the various processes and procedures associated with cold chain logistics, including a discussion on its historical evolution. It also elaborates on the key steps involved in cold chain logistic operations of temperature-sensitive vaccines, including cold chain storage, packaging, transportation and monitoring. Further, the chapter provides a brief overview of vaccines which require cold chain operations, along with inputs on their preferred storage / transportation temperature ranges. It also features a discussion on the various modes of transportation used for such shipments. Further, the chapter includes a discussion on the various advantages and limitations associated with cold chain logistics and management industry.

Chapter 4 features a detailed discussion on various complexities associated with the cold chain logistics operations for vaccines (including COVID-19 vaccine). It also highlights the criticality of cold chain logistics during product manufacturing, storage, packaging and transportation. Furthermore, it provides information on recommended cold chain temperature profiles and best practices for shipping and storage of such vaccines. The chapter also elaborates on the various challenges related to cold chain for vaccines and their solutions. It further includes an informative multi-valent analysis to highlight the logistical complexities related to vaccines based on several parameters, such as temperature conditions, delivery time restrictions, handling / transportation requirements, and storage related needs.

Chapter 5 includes information on close to 100 industry players offering cold chain logistics services for vaccines based on a number of relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, type of services offered (storage, packaging, and transportation), mode of transportation used (ground, air, and ocean), holding temperature range (ambient, refrigerated, frozen, and deep frozen / cryogenic), type of packaging method adopted (dry ice, liquid nitrogen, and gel packs), type of container used (active and passive containers), end-users (industry players and non-industry players), availability of capabilities for transport of COVID-19 vaccine, location of cold chain facilities. In addition, the chapter includes a list of cold chain equipment / technologies and monitoring systems, along with the information on their developers.

Chapter 6 features a contemporary market trend analysis, which include [A] a tree map representation, comparing industry players on the basis of holding temperature range and company size, [B] a heat map representation comparing players on the basis of holding temperature range and type of packaging method, [C] a grid representation which highlights the distribution of players based on mode of transportation, type of container and region, and [D] a world map representation presenting the regional distribution of players engaged in this domain based on the location of their respective headquarters.

Chapter 7 features an insightful company competitiveness analysis, highlighting prominent logistics service providers based in different regions, taking into consideration their supplier strength (in terms of experience of the service provider), and capabilities related to cold chain logistics (such as type of container, type of service(s) offered, holding temperature range, mode of transportation and region).

Chapter 8 features elaborate profiles of prominent service providers (shortlisted on the basis of the company competitiveness analysis) engaged in this domain. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key members of the executive team), details related to their respective portfolios for cold chain services, recent developments, and an informed future outlook.

Chapter 9 elaborate discussion on the various regulatory guidelines that have been laid down by major regulatory bodies (such as European Medicines Agency (EMA), United States Food and Drug Administration (USFDA), Health Canada (HC), International Air Transport Association (IATA), International Safe Transit Association (ISTA), United States Pharmacopeia (USP), and World Health Organization (WHO)), specific to cold chain management. In addition, it features an insightful analysis, comparing these regulatory authorities based on the guidelines issued by them for different stages of the cold chain.

Chapter 10 provides detailed analysis of the partnerships that have been established in the cold chain logistics market for vaccines, during the period between 2010 and 2020, covering service alliances, logistics services agreements, merger / acquisitions, equipment development / manufacturing agreements, R&D agreements, joint ventures and other relevant deals.

Chapter 11 provides a detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in terms of the number of companies acquired till 2020, along with the geographical distribution of this activity.

Chapter 12 features detailed estimation of the likely demand for logistics services for vaccines (including over 15 types of mandatory and optional vaccines), considering the contributions from both clinical and commercially available products for infants and adults, over the period 2020-2030.

Chapter 13 highlights the impact of COVID-19 pandemic on the cold chain logistics market for vaccines. In addition, it features a brief discussion on the key initiatives undertaken by key pharma players and key strategies to mitigate the challenges associated with logistics of COVID-19 vaccine. 

Chapter 14 presents an insightful market forecast analysis, highlighting the future potential of cold chain logistics market till 2030. We have segmented the market on the basis of [A] holding temperature ranges (refrigerated, frozen, and cryogenic), [B] type of containers (active and passive containers), [C] type of end-users (industry players and non-industry players), and [D] key geographies (North America, Europe, Asia-Pacific, Latin America (LATM), Middle East and North Africa (MENA) and Rest of the World).

Chapter 15 presents discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the cold chain logistics market for vaccines.

Chapter 16 features a detailed discussion on the upcoming tools / technologies (such as integration of automation and robotics, cloud computing, blockchain technology, artificial intelligence and other such advanced technical solutions) in the field of cold chain logistics and their likely impact on the future evolution of this market.

Chapter 17 summarizes the overall report, wherein we have mentioned all the key facts and figures described in the previous chapters. The chapter also highlights important evolutionary trends that were identified during the course of the study and are expected to influence the future of the cold chain logistics market for vaccines. 

Chapter 18 is a collection of transcripts of interviews conducted with various stakeholders in the industry. The chapter provides a brief overview of the companies and details of interviews held with Elena Boykova (Marketing Communications Manager, AirBridgeCargo Airlines), Jacqueline Barry (Chief Clinical Officer, Catapult Cell and Gene Therapy), Michelle Arnot-Kruger (Health Specialist, Cold Chain Logistics, UNICEF), and Shehdeh Abusnineh (Supply Chain Manager, Tabuk Pharmaceuticals).

Chapter 19 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 20 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Concept of Cold Chain Logistics
3.2.1. Comparison of Conventional Supply Chain and Cold Chain
3.2.2. Historical Evolution of the Cold Chain Logistics Industry

3.3. Cold Chain Logistics in Healthcare
3.4. Types of Healthcare Products Requiring Cold Chain Logistics

3.5. Types of Containers Used in Cold Chain Logistics
3.5.1. Active Cold Chain Containers
3.5.2. Passive Cold Chain Containers
3.5.3. Insulated Cold Chain Containers

3.6. Modes of Transportation Used in Cold Chain Logistics
3.6.1. Road Transportation
3.6.2. Air Transportation
3.6.3. Ocean / Marine Transportation
3.6.4. Rail Transportation
3.6.5. Intermodal and Multimodal Transportation
3.6.6. Comparison of Modes of Transportation

3.7. Advantages and Limitations of Cold Chain Logistics in Healthcare
3.8. Concluding Remarks

4. COLD CHAIN LOGISTICS FOR VACCINES
4.1. Chapter Overview
4.2. Introduction to Vaccines 
4.3. Classification of Vaccines 
4.4. Overview of Vaccine Logistics
4.5. Cold Storage 

4.6. Challenges Related to Transporting Vaccines 
4.6.1. Heat Sensitivity 
4.6.2. Cross-Border Shipment Concerns
4.6.3. Container Related Concerns 

4.7. Concluding Remarks

5. CURRENT MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Cold Chain Logistics Service Providers for Vaccines: List of Players
5.2.1. Analysis by Year of Establishment 
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters 
5.2.4. Analysis by Type of Cold Chain Logistics Service(s) Offered 
5.2.5. Analysis by Mode of Transportation 
5.2.6. Analysis by Holding Temperature Range 
5.2.7. Analysis by Type of Packaging Method
5.2.8. Analysis by Type of Container Used
5.2.9. Analysis by End-User 
5.2.10. Analysis by Location of Cold Chain Facility

5.3. Cold Chain for COVID-19 Vaccines: Key Initiatives Undertaken by Logistics Service Providers
5.3.1. Analysis by Capabilities for COVID-19 Vaccine Transport

5.4. List of Equipment / Technologies Available for Cold Chain Logistics of Vaccines

6. KEY INSIGHTS
6.1. Chapter Overview
6.2. Analysis by Holding Temperature Range and Company Size
6.3. Analysis by Holding Temperature Range and Type of Packaging Method
6.4. Analysis by Mode of Transportation, Type of Container and Geographical Activity
6.5. Analysis by Location of Headquarters

7. COMPANY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Key Assumptions and Parameters

7.3. Methodology
7.3.1. Company Competitiveness: Service Providers in North America
7.4.2. Company Competitiveness: Service Providers in Europe
7.4.3. Company Competitiveness: Service Providers in Asia-Pacific
7.4.4. Company Competitiveness: Service Providers in Latin America
7.4.5. Company Competitiveness: Service Providers in Middle East and North Africa (MENA) and Rest of the World (RoW)

7.4. Company Competitiveness: Benchmarking the Capabilities of Leading Players

8. COMPANY PROFILES
8.1. Chapter Overview
8.2. Cryoport
8.2.1. Company Snapshot
8.2.2. Service / Product Portfolio 
8.2.3. Recent Developments and Future Outlook 

8.3. DHL Express
8.3.1. Company Snapshot
8.3.2. Service / Product Portfolio 
8.3.3. Recent Developments and Future Outlook 

8.4. GAC
8.4.1. Company Snapshot
8.4.2. Service / Product Portfolio
8.4.3. Recent Developments and Future Outlook 

8.5. Lynden International Logistics
8.5.1. Company Snapshot
8.5.2. Service / Product Portfolio 
8.5.3. Recent Developments and Future Outlook 

8.6. PAREXEL
8.6.1. Company Snapshot
8.6.2. Service / Product Portfolio 
8.6.3. Recent Developments and Future Outlook 

8.7. United Parcel Service
8.7.1. Company Snapshot
8.7.2. Service / Product Portfolio 
8.7.3. Recent Developments and Future Outlook 

8.8. Yusen Logistics 
8.8.1. Company Snapshot
8.8.2. Service / Product Portfolio
8.8.3. Recent Developments and Future Outlook 

9. REGULATORY RECOMMENDATIONS AND GUIDELINES
9.1. Chapter Overview
9.2. Regulatory Guidelines Issued by International Authorities
9.2.1. World Health Organization (WHO)
9.2.2. International Air Transport Association (IATA)
9.2.3. International Safe Transit Association (ISTA)

9.3. Regulatory Guidelines for Cold Chain Management in the US
9.3.1. United States Food and Drug Administration (USFDA)
9.3.2. United States Pharmacopeia (USP)

9.4. Regulatory Guidelines for Cold Chain Management in Canada
9.4.1. Health Canada
9.5. Regulatory Guidelines for Cold Chain Management in Europe
9.5.1. European Medicine Agency (EMA)

9.6. Recommendations for Different Steps of Cold Chain Logistics
9.7. Comparative Analysis of Regulatory Authorities

10. PARTNERHSIPS AND COLLABORATIONS 
10.1. Chapter Overview
10.2. Partnership Models
10.3. Cold Chain Logistics for Vaccines: Recent Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.2.1. Analysis by Year of Partnership and Type of Partnership
10.3.2.2. Analysis by Type of Partnership and Company Size

10.3.3 Analysis by Type of Cold Chain Logistics Service Offered
10.3.3.1. Analysis by Year of Partnership and Type of Cold Chain Logistics Service Offered
10.3.3.2. Analysis by Type of Partnership and Type of Cold Chain Logistics Service Offered

10.3.4. Most Active Players: Analysis by Number of Partnerships 
10.3.5. Analysis by Region
10.3.5.1. Intercontinental and Intracontinental Agreements

11. MERGERS AND ACQUISITIONS
11.1. Chapter Overview
11.2. Cold Chain Logistics for Vaccines: Mergers and Acquisitions 
11.2.1. Analysis by Year of Merger / Acquisition
11.2.2. Analysis by Region
11.2.3. Most Active Acquirers: Analysis by Number of Acquisitions
11.2.4. Most Active Acquirers: Key Value Drivers
11.3. Cold Chain Logistics for Vaccines: Recent Expansions
11.3.1. Analysis by Year of Expansion

12. DEMAND ANALYSIS FOR VACCINES
12.1. Chapter Overview
12.2. Scope and Methodology

12.3. Global Clinical Demand for Vaccines (Clinical Trial Analysis) 
12.3.1. Analysis by Trial Registration Year
12.3.2. Analysis by Holding Temperature Range
12.3.3. Analysis by Type of Vaccine
12.3.4. Analysis by Trial Phase
12.3.5. Analysis by Trial Status
12.3.6. Analysis by Number of Clinical Trials and Region
12.3.7. Analysis by Trial Status, Trial Phase and Region
12.3.8. Analysis by Type of Sponsor / Collaborator
12.3.9. Most Active Players: Analysis by Number of Clinical Trials

12.4. Global Clinical Demand for Vaccines (Analysis of Enrolled Patient Population)
12.4.1. Analysis by Enrolled Patient Population and Region
12.4.2. Analysis of Enrolled Patient Population by Trial Phase, Holding Temperature Range and Region
12.4.3. Analysis of Enrolled Patient Population by Trial Phase, Type of Vaccine and Region

12.5. Global Commercial Demand for Vaccines (Annual Number of Doses Required)
12.5.1. Analysis by Type of Vaccine 
12.5.2. Analysis for Mandatory Vaccines by Number of Doses and Region
12.5.3. Analysis for Optional Vaccines by Number of Doses and Region
12.5.3.1. Analysis for COVID-19 Vaccines by Number of Doses and Region

12.6. Global Commercial Demand for Vaccines (Target Patient Population)

12.7. Concluding Remarks

13. COLD CHAIN LOGISTICS FOR COVID-19 VACCINE
13.1. Chapter Overview
13.2. Impact of COVID-19 Outbreak on Cold Chain Logistics for Vaccines
13.3. Impact on Future Market Opportunities for Cold Chain Logistics Service Providers for Vaccines
13.4. Current Opinions and Key Initiatives of Key Players
13.5. Strategies to Address the Challenges Associated with COVID-19 Vaccine Logistics
13.5.1. Strategies for Implementation in the Short / Mid Term
13.5.2. Strategies for Implementation in the Long Term

14. MARKET FORECAST
14.1. Chapter Overview
14.2. Forecast Methodology and Key Assumptions
14.3. Global Cold Chain Logistics Market for Vaccines, 2020-2030

14.4. Global Cold Chain Logistics Market for Vaccines: Distribution by Holding Temperature Range
14.4.1. Cold Chain Logistics Market for Vaccines Requiring Refrigerated Temperature, 2020-2030
14.4.2. Cold Chain Logistics Market for Vaccines Requiring Frozen Temperature, 2020-2030
14.4.3. Cold Chain Logistics Market for Vaccines Requiring Cryogenic Temperature, 2020-2030

14.5. Global Cold Chain Logistics Market for Vaccines: Distribution by Type of Container
14.5.1. Cold Chain Logistics Market for Vacinnes for Active Containers, 2020-2030
14.5.2. Cold Chain Logistics Market for Vaccines for Passive Containers, 2020-2030

14.6. Global Cold Chain Logistics Market for Vaccines: Distribution by Type of End-User
14.6.1. Cold Chain Logistics Market for Vaccines for Industry Players, 2020-2030
14.6.2. Cold Chain Logistics Market for Vaccines for Non-Industry Players, 2020-2030

14.7. Global Cold Chain Logistics Market for Vaccines: Distribution by Geography
14.7.1. Cold Chain Logistics Market for Vaccines in North America, 2020-2030
14.7.1.1. Cold Chain Logistics Market for Vaccines in the US, 2020-2030
14.7.1.2. Cold Chain Logistics Market for Vaccines in Canada, 2020-2030

14.7.2. Cold Chain Logistics Market for Vaccines in Europe, 2020-2030
14.7.2.1. Cold Chain Logistics Market for Vaccines in the UK, 2020-2030
14.7.2.2. Cold Chain Logistics Market for Vaccines in Germany, 2020-2030
14.7.2.3. Cold Chain Logistics Market for Vaccines in France, 2020-2030
14.7.2.4. Cold Chain Logistics Market for Vaccines in Spain, 2020-2030
14.7.2.5. Cold Chain Logistics Market for Vaccines in Italy, 2020-2030
14.7.2.6. Cold Chain Logistics Market for Vaccines in Rest of Europe, 2020-2030

14.7.3. Cold Chain Logistics Market for Vaccines in Asia-Pacific, 2020-2030
14.7.3.1. Cold Chain Logistics Market for Vaccines in Australia, 2020-2030
14.7.3.2. Cold Chain Logistics Market for Vaccines in China, 2020-2030
14.7.3.3. Cold Chain Logistics Market for Vaccines in Japan, 2020-2030
14.7.3.4. Cold Chain Logistics Market for Vaccines in India, 2020-2030
14.7.3.5. Cold Chain Logistics Market for Vaccines in Rest of Asia-Pacific, 2020-2030

14.7.4. Cold Chain Logistics Market for Vaccines in Latin America, 2020-2030
14.7.4.1. Cold Chain Logistics Market for Vaccines in Brazil, 2020-2030
14.7.4.2. Cold Chain Logistics Market for Vaccines in Mexico, 2020-2030
14.7.4.3. Cold Chain Logistics Market for Vaccines in Rest of Latin America, 2020-2030

14.7.5. Cold Chain Logistics Market for Vaccines in Middle East and North Africa (MENA), 2020-2030
14.7.5.1. Cold Chain Logistics Market for Vaccines in Iraq, 2020-2030
14.7.4.2. Cold Chain Logistics Market for Vaccines in Israel, 2020-2030
14.7.4.3. Cold Chain Logistics Market for Vaccines in Rest of MENA, 2020-2030

14.7.5. Cold Chain Logistics Market for Vaccines in Rest of the World, 2020-2030

14.8. Concluding Remarks

15. SWOT ANALYSIS
15.1. Chapter Overview
15.2. Comparison of SWOT Factors
15.2.1. Strengths
15.2.2. Weakness
15.2.3. Opportunities
15.2.4. Threats

15.3. Concluding Remarks

16. UPCOMING TRENDS AND FUTURE GROWTH OPPORTUNITIES
16.1. Chapter Overview
16.2. Connected Cold Chain: Key Tools and Affiliated Technologies
16.2.1. Artificial Intelligence 
16.2.2. Augmented Reality
16.2.3. Automation and Robotics 
16.2.4. Big Data Analytics
16.2.5. Blockchain Technology
16.2.6. Cloud Computing 
16.2.7. Internet of Things 
16.2.8. Radio Frequency Identification (RFID) Tags

16.3. Connected Cold Chain: Future Growth Opportunities

16.4. Real-Time Monitoring: An Application of Connected Cold Chain Solutions
16.4.1. Methods for Integration of Real-Time Monitoring in Cold Chain Logistics
16.4.1.1. RFID Based Real-Time Monitoring
16.4.1.2. Blockchain and IoT Based Real-Time Monitoring
16.4.2. Growth Opportunities for Real-Time Monitoring in Connected Cold Chain
16.4.3. Cost Benefits of Real-Time Monitoring in Cold Chain Logistics

17. CONCLUSION

18. EXECUTIVE INSIGHTS
18.1. Chapter Overview
18.2. AirBridgeCargo Airlines
18.2.1. Company Snapshot
18.2.2. Interview Transcript: Elena Boykova, Marketing Communications Manager

18.3. Cell and Gene Therapy Catapult
18.3.1. Company Snapshot
18.3.2. Interview Transcript: Jacqueline Barry, Chief Clinical Officer

18.4. UNICEF
18.4.1. Company Snapshot
18.4.2. Interview Transcript: Michelle Arnot-Kruger, Health Specialist, Cold Chain Logistics

18.5. Tabuk Pharmaceuticals
18.5.1. Company Snapshot
18.5.2. Interview Transcript: Shehdeh Abusnineh, Supply Chain Manager

19. APPENDIX 1: TABULATED DATA

20. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Key Steps Involved in the Supply Chain
Figure 3.2 Differences between Conventional Supply Chain and Cold Chain
Figure 3.3 Key Historical Milestones in the Cold Chain Logistics Industry
Figure 3.4 Applications of Cold Chain Logistics
Figure 3.5 Key Components of Cold Chain Logistics Process
Figure 3.6 Types of Healthcare Products requiring Cold Chain Logistics
Figure 3.7 Recommended Holding Temperature Ranges for Various Healthcare Products
Figure 3.8 Types of Active Cold Chain Containers
Figure 3.9 Types of Materials / Methods used in Passive Cold Chain Containers
Figure 3.10 Types of Insulated Cold Chain Containers
Figure 3.11 Key Considerations for Management of Road Shipments
Figure 3.12 Key Considerations for Management of Road Shipments using Passive Cold Chain Containers
Figure 3.13 Types of Carriers for Air Transportation
Figure 3.14 Key Considerations for Management of Air Shipments
Figure 3.15 Advantages and Limitations of Cold Chain Logistics in Healthcare
Figure 4.1 Key Steps in Vaccine Transportation Process
Figure 4.2 Key Considerations for Storage of Vaccines
Figure 4.3 Heat Sensitivity of Different Types of Vaccines
Figure 4.4 Types of Containers for Transportation of Vaccines
Figure 5.1 Cold Chain Logistics Service Providers for Vaccines: Distribution by Year of Establishment
Figure 5.2 Cold Chain Logistics Service Providers for Vaccines: Distribution by Company Size
Figure 5.3 Cold Chain Logistics Service Providers for Vaccines: Distribution by Location of Headquarters
Figure 5.4 Cold Chain Logistics Service Providers for Vaccines: Distribution by Type of Service(s) Offered
Figure 5.5 Cold Chain Logistics Service Providers for Vaccines: Distribution by Mode of Transportation
Figure 5.6 Cold Chain Logistics Service Providers for Vaccines: Distribution by Holding Temperature Range
Figure 5.7 Cold Chain Logistics Service Providers for Vaccines: Distribution by Type of Packaging Method
Figure 5.8 Cold Chain Logistics Service Providers for Vaccines: Distribution by Type of Container Used
Figure 5.9 Cold Chain Logistics Service Providers for Vaccines: Distribution by End-User
Figure 5.10 Cold Chain Logistics Service Providers for Vaccines: Distribution by Location of Cold Chain Facility
Figure 5.11 Cold Chain Logistics Service Providers: Distribution by Capabilities for COVID-19 Vaccine Transport
Figure 6.1 Tree Map Representation: Distribution by Holding Temperature Range and Company Size
Figure 6.2 Heat Map Representation: Distribution by Holding Temperature Range and Type of Packaging Method
Figure 6.3 Grid Analysis: Distribution by Mode of Transportation, Type of Container and Geographical Activity
Figure 6.4 World Map Representation: Distribution by Location of Headquarters
Figure 7.1 Company Competitiveness Analysis: Cold Chain Logistics Service Providers for Vaccines in North America
Figure 7.2 Company Competitiveness: Cold Chain Logistics Service Providers for Vaccines in Europe
Figure 7.3 Company Competitiveness: Cold Chain Logistics Service Providers for Vaccines in Asia-Pacific
Figure 7.4 Company Competitiveness: Cold Chain Logistics Service Providers for Vaccines in Latin America
Figure 7.5 Company Competitiveness: Cold Chain Logistics Service Providers for Vaccines in Middle East and North Africa and Rest of the World
Figure 7.6 Company Competitiveness: Leading Cold Chain Logistics Service Providers for Vaccines
Figure 8.1 Cryoport: Cold Chain Logistics Services / Products
Figure 8.2 DHL Express: Cold Chain Logistics Services / Products
Figure 8.3 GAC: Cold Chain Logistics Services / Products
Figure 8.4 Lynden International Logistics: Cold Chain Logistics Services / Products
Figure 8.5 PAREXEL: Cold Chain Logistics Services / Products
Figure 8.6 United Parcel Service: Cold Chain Logistics Services / Products
Figure 8.7 Yusen Logistics: Cold Chain Logistics Services / Products
Figure 9.1 Cold Chain Logistics in Vaccines: International and Regional Regulatory Authorities
Figure 9.2 WHO Guidelines for Cold Chain Logistics
Figure 9.3 IATA (CEIV Pharma) Guidelines for Cold Chain Logistics
Figure 9.4 ISTA Guidelines for Cold Chain Logistics
Figure 9.5 USFDA Guidelines for Cold Chain Logistics
Figure 9.6 USFDA Form483s Excerpts: Challenges and Solutions Related to Cold Chain Logistics
Figure 9.7 USP Guidelines for Cold Chain Logistics
Figure 9.8 EMA Guidelines for Cold Chain Logistics
Figure 9.9 Regulatory Requirements for Various Steps of Cold Chain Logistics
Figure 9.10 Comparative Analysis of Regulatory Authorities
Figure 10.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2010-2020
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Figure 10.4 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
Figure 10.5 Partnerships and Collaborations: Distribution by Type of Partner
Figure 10.6 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 10.7 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 10.8 Partnerships and Collaborations: Distribution by Type of Cold Chain Logistics Service(s) Offered
Figure 10.9 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Cold Chain Logistics Service(s) Offered
Figure 10.10 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Cold Chain Logistics Service(s) Offered
Figure 10.11 Most Active Players: Distribution by Number of Partnerships
Figure 10.12 Partnerships and Collaborations: Distribution by Region
Figure 10.13 Partnerships and Collaborations: Distribution by Intercontinental and Intracontinental Agreements
Figure 11.1 Mergers and Acquisitions: Cumulative Year-Wise Trend, 2010-2020
Figure 11.2 Mergers and Acquisitions: Distribution by Region
Figure 11.3 Mergers and Acquisitions: Distribution by Intercontinental and Intracontinental Acquisitions
Figure 11.4 Most Active Acquirers: Distribution by Number of Acquisitions
Figure 11.5 Mergers and Acquisitions: Key Value Drivers
Figure 11.6 Heat Map Analysis: Distribution by Key Value Drivers and Year of Acquisition
Figure 11.7 Recent Expansions: Cumulative Year-Wise Trend, 2010-2020
Figure 12.1 Global Clinical Trials Demand for Vaccines: Cumulative Distribution by Registration Year
Figure 12.2 Global Clinical Trials Demand for Vaccines: Distribution by Trial Status
Figure 12.3 Global Clinical Trials Demand for Vaccines: Distribution by Holding Temperature Range
Figure 12.4 Global Clinical Demand for Vaccines: Distribution by Type of Vaccine
Figure 12.5 Global Clinical Demand for Vaccines: Distribution by Trial Phase
Figure 12.6 Global Clinical Trials Demand for Vaccines: Distribution by Number of Trials and Region
Figure 12.7 Global Clinical Trials Demand for Vaccines: Distribution by Trial Status, Trial Phase and Region
Figure 12.8 Global Clinical Trials Demand for Vaccines: Distribution by Type of Sponsor / Collaborator
Figure 12.9 Global Clinical Demand for Vaccines: Most Active Industry Players in Terms of Number of Trials Conducted
Figure 12.10 Most Active Non-Industry Players: Distribution by Number of Trials
Figure 12.11 Global Clinical Trials Demand for Vaccines: Distribution by Enrolled Patient Population
Figure 12.12 Global Clinical Demand for Vaccines: Distribution by Enrolled Patient Population and Region
Figure 12.13 Global Clinical Demand for Vaccines: Distribution of Enrolled Patient Population by Trial Phase, Holding Temperature Range and Region
Figure 12.14 Global Clinical Demand for Vaccines: Distribution of Enrolled Patient Population by Trial Phase, Type of Vaccine and Region
Figure 12.15 Global Commercial Demand for Vaccines: Distribution by Annual Number of Doses Required
Figure 12.16 Global Commercial Demand for Vaccines: Distribution by Type of Vaccine
Figure 12.17 Global Commercial Demand for Mandatory Vaccines: Distribution by Number of Doses and Region
Figure 12.18 Global Commercial Demand for Optional Vaccines: Distribution by Number of Doses and Region
Figure 12.19 Global Commercial Demand for COVID-19 Vaccines: Distribution by Number of Doses and Region
Figure 12.20 Global Commercial Demand for Vaccines: Distribution by Target Patient Population
Figure 12.21 Global Commercial Demand for Vaccines: Distribution by Patient Population (2020, 2025 and 2030)
Figure 12.22 Global Commercial Demand for Vaccines: Distribution by Number of Doses (2020, 2025 and 2030)
Figure 13.1 Global Cold Chain Logistics Market for Vaccines, 2020-2030: COVID-19 Impact Scenario (USD Million)
Figure 14.1 Global Cold Chain Logistics Market for Vaccines, 2020-2030 (USD Million)
Figure 14.2 Global Cold Chain Logistics Market for Vaccines: Distribution by Holding Temperature Range, 2020 and 2030
Figure 14.3 Cold Chain Logistics Market for Vaccines Requiring Refrigerated Temperature, 2020-2030 (USD Million)
Figure 14.4 Cold Chain Logistics Market for Vaccines Requiring Frozen Temperature, 2020-2030 (USD Million)
Figure 14.5 Cold Chain Logistics Market for Vaccines Requiring Cryogenic Temperature, 2020-2030 (USD Million)
Figure 14.6 Global Cold Chain Logistics Market for Vaccines: Distribution by Type of Container, 2020 and 2030
Figure 14.7 Cold Chain Logistics Market for Vacinnes for Active Containers, 2020-2030 (USD Million)
Figure 14.8 Cold Chain Logistics Market for Vaccines for Passive Containers, 2020-2030 (USD Million)
Figure 14.9 Global Cold Chain Logistics Market for Vaccines: Distribution by Type of End-User, 2020 and 2030
Figure 14.10 Cold Chain Logistics Market for Vaccines of Industry Players, 2020-2030 (USD Million)
Figure 14.11 Cold Chain Logistics Market for Vaccines of Non-Industry Players, 2020-2030 (USD Million)
Figure 14.12 Global Cold Chain Logistics Market for Vaccines: Distribution by Geography, 2020 and 2030
Figure 14.13 Cold Chain Logistics Market for Vaccines in North America, 2020-2030 (USD Million)
Figure 14.14 Cold Chain Logistics Market for Vaccines in the US, 2020-2030 (USD Million)
Figure 14.15 Cold Chain Logistics Market for Vaccines in Canada, 2020-2030 (USD Million)
Figure 14.16 Cold Chain Logistics Market for Vaccines in Europe, 2020-2030 (USD Million)
Figure 14.17 Cold Chain Logistics Market for Vaccines in the UK, 2020-2030 (USD Million)
Figure 14.18 Cold Chain Logistics Market for Vaccines in Germany, 2020-2030 (USD Million)
Figure 14.19 Cold Chain Logistics Market for Vaccines in France, 2020-2030 (USD Million)
Figure 14.20 Cold Chain Logistics Market for Vaccines in Spain, 2020-2030 (USD Million)
Figure 14.21 Cold Chain Logistics Market for Vaccines in Italy, 2020-2030 (USD Million)
Figure 14.22 Cold Chain Logistics Market for Vaccines in Rest of Europe, 2020-2030 (USD Million)
Figure 14.23 Cold Chain Logistics Market for Vaccines in Asia-Pacific, 2020-2030 (USD Million)
Figure 14.24 Cold Chain Logistics Market for Vaccines in Australia, 2020-2030 (USD Million)
Figure 14.25 Cold Chain Logistics Market for Vaccines in China, 2020-2030 (USD Million)
Figure 14.26 Cold Chain Logistics Market for Vaccines in Japan, 2020-2030 (USD Million)
Figure 14.27 Cold Chain Logistics Market for Vaccines in India, 2020-2030 (USD Million)
Figure 14.28 Cold Chain Logistics Market for Vaccines in Rest of Asia-Pacific, 2020-2030 (USD Million)
Figure 14.29 Cold Chain Logistics Market for Vaccines in Latin America, 2020-2030 (USD Million)
Figure 14.30 Cold Chain Logistics Market for Vaccines in Brazil, 2020-2030 (USD Million)
Figure 14.31 Cold Chain Logistics Market for Vaccines in Mexico, 2020-2030 (USD Million)
Figure 14.32 Cold Chain Logistics Market for Vaccines in Rest of Latin America, 2020-2030 (USD Million)
Figure 14.33 Cold Chain Logistics Market for Vaccines in Middle East and North Africa (MENA), 2020-2030 (USD Million)
Figure 14.34 Cold Chain Logistics Market for Vaccines in Iraq, 2020-2030 (USD Million)
Figure 14.35 Cold Chain Logistics Market for Vaccines in Israel, 2020-2030 (USD Million)
Figure 14.36 Cold Chain Logistics Market for Vaccines in Rest of MENA, 2020-2030 (USD Million)
Figure 14.37 Cold Chain Logistics Market for Vaccines in Rest of the World, 2020-2030 (USD Million)
Figure 14.38 Cold Chain Logistics Market for Vaccines: Conservative, Base and Optimistic Scenarios, 2020, 2025 and 2030 (USD Million)
Figure 15.1 Cold Chain Logistics Market for Vaccines: SWOT Analysis
Figure 15.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 16.1 Connected Cold Chain Solutions: Process Flow Diagram
Figure 16.2 Artificial Intelligence in Cold Chain Logistics: Key Benefits and Challenges
Figure 16.3 Augmented Reality in Cold Chain Logistics: Key Benefits and Challenges
Figure 16.4 Automation and Robotics in Cold Chain Logistics: Key Benefits and Challenges
Figure 16.5 Big Data Analytics in Cold Chain Logistics: Key Benefits and Challenges
Figure 16.6 Blockchain Technology in Cold Chain Logistics: Key Benefits and Challenges
Figure 16.7 Cloud Computing in Cold Chain Logistics: Key Benefits and Challenges
Figure 16.8 Internet of Things in Cold Chain Logistics: Schematic Representation
Figure 16.9 Internet of Things in Cold Chain Logistics: Key Benefits and Challenges
Figure 16.10 RFID in Cold Chain Logistics: Key Benefits and Challenges
Figure 16.11 Connected Cold Chain: Harvey Ball Analysis of Future Growth Opportunities
Figure 16.12 Real-Time Monitoring: Conventional Devices
Figure 16.13 RFID Based Real-Time Monitoring in Cold Chain Logistics
Figure 16.14 Key Contributions of Blockchain Technology and IoT in Real-Time Monitoring
Figure 16.15 Blockchain Technology and IoT Based Real-Time Monitoring: Flow Diagram
Figure 16.16 Real-Time Monitoring in Cold Chain Management: Growth Opportunities
Figure 16.17 Real-Time Monitoring: Reduction in Cost of Cold Chain Logistics
Figure 17.1 Concluding Remarks: Current Market Landscape
Figure 17.2 Concluding Remarks: Partnerships and Collaborations
Figure 17.3 Concluding Remarks: Mergers / Acquisitions
Figure 17.4 Concluding Remarks: Global Demand for Vaccines
Figure 17.5 Concluding Remarks: Market Sizing and Opportunity Analysis

List Of Tables

Table 3.1 Comparison of Different Modes of Transportation
Table 4.1 Classification of Vaccines Based on Method of Development
Table 4.2 Recommended Holding Temperature Ranges for Different Type of Vaccines
Table 4.3 Logistics Complexity Analysis for Vaccines
Table 5.1 Cold Chain Logistics Service Providers: List of Industry Players
Table 5.2 Cold Chain Logistics Service Providers: List of Services Offered
Table 5.3 Cold Chain Logistics Service Providers: List of Mode of Transportation
Table 5.4 Cold Chain Logistics Service Providers: List of Holding Temperature Range
Table 5.5 Cold Chain Logistics Service Providers: List of Type of Container Used
Table 5.6 Cold Chain Logistics Service Providers: List of End-Users
Table 5.7 Cold Chain Logistics Service Providers: List of Location of Cold Chain Facility (Continent-wise)
Table 5.8 Cold Chain Logistics Service Providers: List of Location of Cold Chain Facility (Country-wise)
Table 5.9 List of Equipment / Technologies for Cold Chain Logistics of Vaccines
Table 8.1 Cold Chain Logistics Service Providers: List of Companies Profiled
Table 8.2 Cryoport: Company Snapshot
Table 8.3 Cryoport: Recent Developments and Future Outlook
Table 8.4 DHL Express: Company Snapshot
Table 8.5 DHL Express: Recent Developments and Future Outlook
Table 8.6 GAC: Company Snapshot
Table 8.7 GAC: Recent Developments and Future Outlook
Table 8.8 Lynden International Logistics: Company Snapshot
Table 8.9 Lynden International Logistics: Recent Developments and Future Outlook
Table 8.10 PAREXEL: Company Snapshot
Table 8.11 PAREXEL: Recent Developments and Future Outlook
Table 8.12 United Parcel Service: Company Snapshot
Table 8.13 United Parcel Service: Recent Developments and Future Outlook
Table 8.14 Yusen Logistics: Company Snapshot
Table 8.15 Yusen Logistics: Recent Developments and Future Outlook
Table 10.1 Partnerships and Collaborations: Information on Year of Agreement, Type of Partnership Model and Partner, 2015-2020
Table 10.2 Partnerships and Collaborations: Information on Type of Agreement and Type of Service(s) Offered, 2015-2020
Table 11.1 Mergers and Acquisitions: List of Agreements, 2015-2020
Table 11.2 Mergers and Acquisitions: Information on Key Value Drivers
Table 11.3 Recent Expansions: List of Expansions, 2015-2020
Table 16.1 Artificial Intelligence in Cold Chain Logistics: List of Companies
Table 16.2 Automation and Robotics in Cold Chain Logistics: List of Companies
Table 16.3 Big Data Analytics in Cold Chain Logistics: List of Companies
Table 16.4 Blockchain Technology in Cold Chain Logistics: List of Companies
Table 16.5 Cloud Computing in Cold Chain Logistics: List of Companies
Table 16.6 Internet of Things in Cold Chain Logistics: List of Companies
Table 16.7 RFID Tags in Cold Chain Logistics: List of Companies
Table 18.1 AirBridgeCargo Airlines: Company Snapshot
Table 18.2 Cell and Gene Therapy Catapult: Company Snapshot
Table 18.3 UNICEF: Company Snapshot
Table 18.4 Tabuk Pharmaceuticals: Company Snapshot
Table 19.1 Cold Chain Logistics Service Providers for Vaccines: Distribution by Year of Establishment
Table 19.2 Cold Chain Logistics Service Providers for Vaccines: Distribution by Company Size
Table 19.3 Cold Chain Logistics Service Providers for Vaccines: Distribution by Location of Headquarters
Table 19.4 Cold Chain Logistics Service Providers for Vaccines: Distribution by Type of Service(s) Offered
Table 19.5 Cold Chain Logistics Service Providers for Vaccines: Distribution by Mode of Transportation
Table 19.6 Cold Chain Logistics Service Providers for Vaccines: Distribution by Holding Temperature Range
Table 19.7 Cold Chain Logistics Service Providers for Vaccines: Distribution by Type of Packaging Method
Table 19.8 Cold Chain Logistics Service Providers for Vaccines: Distribution by Type of Container Used
Table 19.9 Cold Chain Logistics Service Providers for Vaccines: Distribution by End-User
Table 19.10 Cold Chain Logistics Service Providers for Vaccines: Distribution by Location of Cold Chain Facility
Table 19.11 Cold Chain Logistics Service Providers: Distribution by Capabilities for COVID-19 Vaccine Transport
Table 19.12 Tree Map Representation: Distribution by Holding Temperature Range and Company Size
Table 19.13 Heat Map Representation: Distribution by Holding Temperature Range and Type of Packaging Method
Table 19.14 Grid Analysis: Distribution by Mode of Transportation, Type of Container and Geographical Activity
Table 19.15 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2010-2020
Table 19.16 Partnerships and Collaborations: Distribution by Type of Partnership
Table 19.17 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Table 19.18 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
Table 19.19 Partnerships and Collaborations: Distribution by Type of Partner
Table 19.20 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 19.21 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 19.22 Partnerships and Collaborations: Distribution by Type of Cold Chain Logistics Service(s) Offered
Table 19.23 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Cold Chain Logistics Service(s) Offered
Table 19.24 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Cold Chain Logistics Service(s) Offered
Table 19.25 Most Active Players: Distribution by Number of Partnerships
Table 19.26 Partnerships and Collaborations: Distribution by Region
Table 19.27 Partnerships and Collaborations: Distribution by Intercontinental and Intracontinental Agreements
Table 19.28 Mergers and Acquisitions: Cumulative Year-Wise Trend, 2010-2020
Table 19.29 Mergers and Acquisitions: Distribution by Region
Table 19.30 Mergers and Acquisitions: Distribution by Intercontinental and Intracontinental Acquisitions
Table 19.31 Most Active Acquirers: Distribution by Number of Acquisitions
Table 19.32 Mergers and Acquisitions: Key Value Drivers
Table 19.33 Heat Map Analysis: Distribution by Key Value Drivers and Year of Acquisition
Table 19.34 Recent Expansions: Cumulative Year-Wise Trend, 2010-2020
Table 19.35 Global Clinical Trials Demand for Vaccines: Cumulative Distribution by Registration Year
Table 19.36 Global Clinical Trials Demand for Vaccines: Distribution by Trial Status
Table 19.37 Global Clinical Trials Demand for Vaccines: Distribution by Holding Temperature Range
Table 19.38 Global Clinical Demand for Vaccines: Distribution by Type of Vaccine
Table 19.39 Global Clinical Demand for Vaccines: Distribution by Trial Phase
Table 19.40 Global Clinical Trials Demand for Vaccines: Distribution by Number of Trials and Region
Table 19.41 Global Clinical Trials Demand for Vaccines: Distribution by Trial Status, Trial Phase and Region
Table 19.42 Global Clinical Trials Demand for Vaccines: Distribution by Type of Sponsor / Collaborator
Table 19.43 Global Clinical Demand for Vaccines: Most Active Industry Players in Terms of Number of Trials Conducted
Table 19.44 Most Active Non-Industry Players: Distribution by Number of Trials
Table 19.45 Global Clinical Trials Demand for Vaccines: Distribution by Enrolled Patient Population
Table 19.46 Global Clinical Demand for Vaccines: Distribution by Enrolled Patient Population and Region
Table 19.47 Global Clinical Demand for Vaccines: Distribution of Enrolled Patient Population by Trial Phase, Holding Temperature Range and Region
Table 19.48 Global Clinical Demand for Vaccines: Distribution of Enrolled Patient Population by Trial Phase, Type of Vaccine and Region
Table 19.49 Global Commercial Demand for Vaccines: Distribution by Annual Number of Doses Required
Table 19.50 Global Commercial Demand for Vaccines: Distribution by Type of Vaccine
Table 19.51 Global Commercial Demand for Mandatory Vaccines: Distribution by Number of Doses and Region
Table 19.52 Global Commercial Demand for Optional Vaccines: Distribution by Number of Doses and Region
Figure 19.53 Global Commercial Demand for COVID-19 Vaccines: Distribution by Number of Doses and Region
Table 19.54 Global Commercial Demand for Vaccines: Distribution by Target Patient Population
Table 19.55 Global Commercial Demand for Vaccines: Distribution by Patient Population (2020, 2025 and 2030)
Table 19.56 Global Commercial Demand for Vaccines: Distribution by Number of Doses (2020, 2025 and 2030)
Table 19.57 Global Cold Chain Logistics Market for Vaccines, 2020-2030: COVID-19 Impact Scenario (USD Million)
Table 19.58 Global Cold Chain Logistics Market for Vaccines, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.59 Global Cold Chain Logistics Market for Vaccines: Distribution by Holding Temperature Range, 2020 and 2030
Table 19.60 Cold Chain Logistics Market for Vaccines Requiring Refrigerated Temperature, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.61 Cold Chain Logistics Market for Vaccines Requiring Frozen Temperature, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.62 Cold Chain Logistics Market for Vaccines Requiring Cryogenic Temperature, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.63 Global Cold Chain Logistics Market for Vaccines: Distribution by Type of Container, 2020 and 2030
Table 19.64 Cold Chain Logistics Market for Vacinnes for Active Containers, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.65 Cold Chain Logistics Market for Vaccines for Passive Containers, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.66 Global Cold Chain Logistics Market for Vaccines: Distribution by Type of End-User, 2020 and 2030
Table 19.67 Cold Chain Logistics Market for Vaccines of Industry Players, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.68 Cold Chain Logistics Market for Vaccines of Non-Industry Players, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.69 Global Cold Chain Logistics Market for Vaccines: Distribution by Geography, 2020 and 2030
Table 19.70 Cold Chain Logistics Market for Vaccines in North America, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.71 Cold Chain Logistics Market for Vaccines in the US, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.72 Cold Chain Logistics Market for Vaccines in Canada, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.73 Cold Chain Logistics Market for Vaccines in Europe, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.74 Cold Chain Logistics Market for Vaccines in the UK, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.75 Cold Chain Logistics Market for Vaccines in Germany, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.76 Cold Chain Logistics Market for Vaccines in France, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.77 Cold Chain Logistics Market for Vaccines in Spain, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.78 Cold Chain Logistics Market for Vaccines in Italy, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.79 Cold Chain Logistics Market for Vaccines in Rest of Europe, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.80 Cold Chain Logistics Market for Vaccines in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.81 Cold Chain Logistics Market for Vaccines in Australia, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.82 Cold Chain Logistics Market for Vaccines in China, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.83 Cold Chain Logistics Market for Vaccines in Japan, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.84 Cold Chain Logistics Market for Vaccines in India, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.85 Cold Chain Logistics Market for Vaccines in Rest of Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.86 Cold Chain Logistics Market for Vaccines in Latin America, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.87 Cold Chain Logistics Market for Vaccines in Brazil, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.88 Cold Chain Logistics Market for Vaccines in Mexico, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.89 Cold Chain Logistics Market for Vaccines in Rest of Latin America, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.90 Cold Chain Logistics Market for Vaccines in Middle East and North Africa (MENA), Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.91 Cold Chain Logistics Market for Vaccines in Iraq, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.92 Cold Chain Logistics Market for Vaccines in Israel, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.93 Cold Chain Logistics Market for Vaccines in Rest of MENA, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.94 Cold Chain Logistics Market for Vaccines in Rest of the World, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)

PRICING DETAILS

USD 5,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com